EDITORIAL COMMENT

Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development*

Maria Vanessa Perez-Gomez, Catalina Martin-Cleary, Beatriz Fernandez-Fernandez and Alberto Ortiz

Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid; Fundacion Renal Inigo Alvarez de Toledo-IRSN and REDINREN, Madrid, Spain

Correspondence and offprint requests to: Alberto Ortiz; E-mail: aortiz@fjd.es

* This article should be listed in pubmed as comment on: Gonzalez-Quiroz M, Pearce N, Caplin B, Nitsch D. What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis. Clin Kidney J 2018

ABSTRACT

Chronic kidney disease of unknown aetiology (CKDu) refers to the epidemic level of incidence of CKD in several low- and middle-income countries, usually near the equator, for which the aetiology has not been identified. CKDu represents a form of CKD hotspot, defined as a country, region, community or ethnicity with a higher than average incidence of CKD. In terms of the number of persons affected, the so-called hypertensive nephropathy of African Americans probably represents the largest CKD hotspot, which is largely driven by variants of the APOL1 gene, questioning the very existence of hypertensive nephropathy and illustrating how kidney disease driven by genetic predisposition may underlie some forms of hypertension. For CKDu, hard physical work leading to dehydration (the first global warming-related disease?) and local toxins are leading aetiological candidates. Meso-American nephropathy is probably the best-characterized CKDu. In this issue of CKJ, the first systematic review and meta-analysis by Gonzalez et al. identified positive associations with male gender, family history of CKD, high water intake and lowland altitude. We now discuss the potential relationship of family history to genetic predisposition and how a better understanding of CKDu may help advance the aetiological characterization of the nearly 50% of end-stage renal disease patients worldwide that have no known cause for CKD or have been assigned non-specific diagnoses.

Keywords: chronic kidney disease of unknown aetiology, CKD hotspot, genetics, Meso-American nephropathy
repeated dehydration episodes [3, 4]. As correctly pointed out by Gonzalez-Quiroz et al. [2], the association with high water intake is difficult to interpret. It may be interpreted as arguing against the hypothesis that dehydration is a driver of CKD in this population, but also as supporting this hypothesis by illustrating high water ingestion needs that may fail to completely replace fluid lost during strenuous physical work. Complicating matters further, polyuria resulting from partial antidiuretic hormone resistance (isosthenuria) reflecting the loss of the urine concentration function of the kidneys is a manifestation of many forms of CKD. Thus the association with a high water intake may simply reflect the existence of CKD. As interesting as the positive associations are the lack of association found for pesticide exposure, alcohol consumption, non-steroidal anti-inflammatory drugs and heat stress, although for the later, a non-significant 50% increase in risk was found [2]. A prior systematic review encompassing worldwide sites of CKDu only shared with the present systematic review the association of CKDu with family history and male sex [5]. We will focus on the association observed in both systematic reviews, the Meso-American and the worldwide CKDu reviews, of CKDu with a family history of CKD, given the potential conceptual impact on our understanding of CKDu beyond CKD hotspots [2, 5]. The association with a family history was reported from both Guatemala and El Salvador, as well as in Southeast Asia [2, 5]. In this regard, three causes of end-stage renal disease (ESRD) in major registries may be considered inaccurate aetiological coding since diagnostic criteria are unclear and the percentage of patients with ESRD attributed to them varies wildly from country to country but overall represents a relatively constant percentage of ESRD patients: unknown aetiology, vascular/hypertensive and chronic pyelonephritis/chronic tubulointerstitial non-cystic disease [6, 7]. Clearly advances in early aetiological diagnosis and therapy are needed if the current worldwide increase in CKD-related premature mortality is to be contained [8]. Genetic factors are obvious candidates, given recent data and advances in the field.

GENETIC PREDISPOSITION TO CKD: NOT LIMITED TO THE YOUNG

Traditionally nephrologists have thought of familial kidney disease in children and younger patients or when family history was present. Indeed, genetic diseases cause 17% (the third most common cause) of ESRD in children and 69–85% (in younger children) and 11% (in older children) of steroid-resistant nephrotic syndrome children [9, 10]. Autosomal dominant polycystic kidney disease (ADPKD) was thought to be the only familial disease that led to ESRD in considerable numbers of more mature patients, with a mean age at the start of dialysis of 55–60 years [11, 12]. However, ADPKD is characterized by large, cystic kidneys, a feature that allowed the diagnosis even before the underlying genetic defects were described. We may hypothesize that genetic diseases without such a striking phenotype may have gone unnoticed, especially if the condition accelerated renal aging, resulting in the potential development of ESRD in the aged. If this is the case, only the identification of the underlying genetic defects will allow the diagnosis of such conditions in the future. In this regard, in Europe a second peak of renal replacement therapy (RRT) incidence at 70–79 years of age, likely due to mutations in PKD2, is almost as high [15–20 per million age-related population (pmarp)] as the classical 55–59 years peak of incidence likely related to PKD1 mutations [12]. Furthermore, the incidence of RRT because of ADPKD at >85 years of age, likely due to PKD2 mutations, is around ~6 pmarp, similar to the incidence in the age range 40–44 years. This high age range may lead physicians to dismiss a genetic cause for kidney disease (Figure 1). The fact that a bona fide monogenic kidney disease has a natural history of up to nine decades is an eye-opener when exploring the potential impact of the genetic background not only on the need for RRT in the aged, but also in the so-called age-associated physiologic decrease of estimated glomerular filtration rate (eGFR) (Figure 2). In this regard, the age range at which genetic screening for steroid-resistant nephrotic syndrome may be informative has increased in recent years. A recent targeted next-generation sequencing panel identified a likely genetic cause in 20% of paediatric and 21% of adult nephrotic cases [13]. Additionally, genetic studies have been informative in adults with CKDu in Western countries. Whole-exome sequencing provided a diagnosis in 24% of 92 adults with CKDu or familial nephropathy or hypertension, encompassing 13 distinct genetic disorders [14]. Nephronophthisis is the most prevalent genetic cause of ESRD in children. However, among 5606 patients with adult-onset ESRD, 0.5% had homozygous deletions in the nephronophthisis-causing gene NPHP1. The median age at ESRD onset was 30 years and the age ranged to 61 years. Most (88%) patients were diagnosed of CKDu [15].

HOW A FAMILY HISTORY OF CKD HELPED IDENTIFY GENETIC PREDISPOSITION TO CKD IN WHAT WAS THOUGHT TO BE KIDNEY DISEASE SECONDARY TO HYPERTENSION

Over the years, medicine has tried to explain the pathophysiology of disease well before the real cause was identified. A major example is the concept of hypertensive nephropathy. Despite its high frequency as a diagnosis for incident RRT patients, the diagnostic criteria are unclear and anchored in tradition and have not been adapted to the evolving concept of CKD. Mann and Hilgers [16] state that the diagnosis of hypertensive nephrosclerosis is generally inferred from the characteristic clinical features: usually a long history of hypertension, a relatively normal urine sediment, small kidneys, and, if previous information is available, slowly progressive renal insufficiency with gradually increasing proteinuria. They further indicate that most important from a clinical viewpoint is that hypertension precedes the development of either proteinuria or renal insufficiency. Finally, there should be no other obvious cause of renal disease [16]. Thus it is a diagnosis of exclusion, made only when no other cause is found: diagnosing hypertensive nephropathy or other nephropathy depends on how hard physicians search for a cause for CKD. Furthermore, we now know that both pathological proteinuria and renal insufficiency are late events in the course of CKD. CKD can be diagnosed when renal function, as assessed by the GFR, and proteinuria are both normal, as long as there is other evidence of kidney injury, such as pathological albuminuria. Thus even when hypertension predates both proteinuria and renal insufficiency, CKD may have predated hypertension. The most dramatic example showing that nephrologists may be mistakenly attributing diverse forms of CKD, including genetic CKD, to hypertension is the demonstration that APO1L gene variants underlie the high frequency of CKD of diverse aetiology in African Americans, including human immunodeficiency virus–associated nephropathy, diabetic nephropathy, focal segmental glomerulosclerosis and, crucially, hypertensive nephropathy [17, 18].
CKD progression is hotly debated [23, 24]. In this regard, when is part of a more generalized predisposition of males to faster despite more severe liver disease in females [22]. Whether this eases, such as ADPKD, progress faster in males than in females, and Fabry disease [19–21], other autosomal genetic kidney dis- 

The fact that male gender is a risk factor for Meso-American nephropathy and ESRD—impact of the environment and ac-

Aetiological factors may differ from CKD hotspot to CKD hot-

Despite the higher risk of Meso-American nephropathy when there is a family history of CKD, the authors rapidly dis-

MALE GENDER AND GENETIC KIDNEY DISEASE
The fact that male gender is a risk factor for Meso-American CKD may be explained by environmental factors such as the triggering effect of hard physical work in a warm humid envi-

A FAMILY HISTORY OF CKD AS A RISK FACTOR FOR MESO-AMERICAN NEPHROPATHY: SUGGESTIVE OF A GENETIC PREDISPOSITION TO KIDNEY DISEASE?
Aetiological factors may differ from CKD hotspot to CKD hot-

FIGURE 1: Genetic predisposition to CKD in the elderly. Kidney sonography of an 85-year-old male who had been diagnosed with primary hypertension and CKD due to hypertensive nephropathy at the ages of 74 and 77 years, respectively. Sonography at age 81 years showed multiple bilateral renal cysts and enlarged 

FIGURE 2: Genetic predisposition and ESRD—impact of the environment and ac-

<60 mL/min/1.73 m² definition and thus the predominance of males was even more striking [2].
neutrophil gelatinase-associated lipocalin (NGAL) is a marker of both acute kidney injury and CKD [28]. In Meso-American nephropathy, sugarcane workers with the largest increases in urinary NGAL:creatinine ratios during the 6-month harvest season had decreasing eGFR levels [29]. Interestingly, in healthy Nicaraguan adolescents 12–18 years of age with no prior work history, urinary NGAL, but not proteinuria, was increased in those regions with the highest Meso-American nephropathy incidence [30]. If the absence of work history is correct, this may imply a genetic predisposition or environmental factors beyond hard working conditions.

**THE WAY FORWARD**

Although Gonzalez-Quiroz et al. [2] identified limitations in the studies included in the meta-analysis, the first meta-analysis in search of risk factors for Meso-American nephropathy provides interesting insights that should be used to drive research. The fact that a family history of CKD is a risk factor for Meso-American nephropathy and that it is the only other risk factor, together with male sex, that is shared by this specific form of CKDu and by other worldwide forms of CKDu is highly suggestive of a potential genetic predisposition. Indeed, it should be considered sufficiently suggestive to perform carefully designed genome-wide association studies and/or whole exome sequencing studies in search of predisposing gene variants that may provide insights into the pathogenesis of the disease and may also be informative about the drivers of CKD in general. The age of genomics is changing many concepts regarding hereditary kidney disease and we hypothesize that it will also become informative for forms of CKD outside the bona fide hereditary kidney diseases [31].

**ACKNOWLEDGEMENTS**

Grant support was provided by ISCIII and FEDER funds, PI16/02057, Sociedad Española de Nefrología, ISCIII-RETIC REDinREN RD016/009, Rio Hortega (to M.V.P.G.), Comunidad de Madrid CIFRA2 B2017/BMD-3686.

**CONFLICT OF INTEREST STATEMENT**

None declared.

**REFERENCES**

1. Martín-Cleary C, Ortiz A. CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. Clin Kidney J 2014; 7: 519–523
2. González-Quiroz M, Pearce N, Caplin B. et al. What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis. Clin Kidney J 2018; 11: 496–506
3. Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. Am J Kidney Dis 2014; 63: 506–520
4. Roncal-Jimenez CA, García-Trabanco R, Wesseling C. et al. Mesoamerican nephropathy or global warming nephropathy? Blood Purif 2016; 41: 135–138
5. Lunyera J, Mohottige D, Von Issenburg M. et al. CKD of uncertain etiology: a systematic review. Clin J Am Soc Nephrol 2016; 11: 379–385
6. Pippias M, Kramer A, Noordzij M. et al. The European Renal Association—European Dialysis and Transplant Association Registry annual report 2014: a summary. Clin Kidney J 2017; 10: 154–169
7. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2015. Amsterdam: Academic Medical Center, Department of Medical Informatics, 2017. https://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2015.pdf (21 June 2018, date last accessed)
8. Sanchez-Niño MD, Sanz AB, Ramos AM. et al. Translational science in chronic kidney disease. Clin Sci 2017; 131: 1617–1629
9. Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet 2018; 392: 61–74
10. ESPN/ERA-EDTA Registry. An Update on the Registry—October 2017. Amsterdam: Academic Medical Center, Department of Medical Informatics 2017. https://www.espn-reg.org/files/AR_2015_dec.pdf (21 June 2018, date last accessed)
11. Rodriguez-Osorio L, Vanessa Perez-Gomez M, Ortiz A. Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD. Kidney Int 2015; 88: 194
12. Spithoven EM, Kramer A, Meijer E. et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int 2014; 86: 1244–1252
13. Sen ES, Dean F, Yarram-Smith L. et al. Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations. J Med Genet 2017; 54: 795–804
14. Lata S, Marasa M, Li Y. et al. Whole-exome sequencing in adults with chronic kidney disease: a pilot study. Ann Intern Med 2018; 168: 100–109
15. Snoek R, van Setten J, Keating RJ. et al. NPHPL1 (Nephrocystin-1) gene deletions cause adult-onset ESRD. J Am Soc Nephrol 2018; 29: 1772–1779
16. Mann J, Hilgers K. Clinical Features, Diagnosis, and Treatment of Hypertensive Nephrosclerosis. In: UpToDate, Waltham, MA. Topic last updated: Aug 28, 2017. http://www.uptodate.com (21 June 2018, date last accessed)
17. Genovese G, Friedman DJ, Ross MD. et al. Association of trypanolytic APOL1 variants with kidney disease in African Americans. Science 2010; 329: 841–845
18. Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008; 19: 2047–2051
19. Kruegel J, Rubel D, Gross O. Alport syndrome—insights from basic and clinical research. Nat Rev Nephrol 2013; 9: 170–178
20. Ortiz A, Oliveira JP, Waldek S. et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008; 23: 1600–1607
21. Ortiz A, Cianciaruso B, Gizmarik M. et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010; 25: 769–775
22. Gansevoort RT, Arici M, Benzing T. et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 2016; 31: 337–348
23. Fernandez-Prado R, Fernandez-Fernandez B, Ortiz A. Women and renal replacement therapy in Europe: lower incidence, equal access to transplantation, longer survival than men. Clin Kidney J 2018; 11: 1–6
24. Piccoli GB, Alrukhaimi M, Liu Z-H. et al. Women and kidney disease: reflections on World Kidney Day 2018. Clin Kidney J 2018; 11: 7–11
25. Limou S, Vince N, Parsa A. Lessons from CKD-related genetic association studies-moving forward. Clin J Am Soc Nephrol 2018; 13: 140–152
26. Udler MS, Nadkarni GN, Belbin G. et al. Effect of genetic african ancestry on eGFR and kidney disease. J Am Soc Nephrol 2015; 26: 1682–1692
27. Langefeld CD, Comeau ME, Ng MCY. et al. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African-Americans with nondiabetic nephropathy than strong APOL1—second gene interactions. Kidney Int 2018; doi: 10.1016/j.kint.2018.03.017
28. Castillo-Rodriguez E, Fernandez-Prado R, Martin-Cleary C. et al. Kidney injury marker 1 and neutrophil gelatinase-associated lipocalin in chronic kidney disease. Nephron 2017; 136: 263–267
29. Laws RL, Brooks DR, Amador JJ. et al. Biomarkers of kidney injury among Nicaraguan sugarcane workers. Am J Kidney Dis 2016; 67: 209–217
30. Ramirez-Rubio O, Amador JJ, Kaufman JS. et al. Urine biomarkers of kidney injury among adolescents in Nicaragua, a region affected by an epidemic of chronic kidney disease of unknown aetiology. Nephrol Dial Transplant 2016; 31: 424–432
31. Ars E, Torra R. Rare diseases, rare presentations: recognizing atypical inherited kidney disease phenotypes in the age of genomics. Clin Kidney J 2017; 10: 586–593